代谢功能障碍相关脂肪性肝病的非药物治疗
本综述概述了生活方式改变/非药物干预对MASLD影响的证据。非药物治疗旨在改善促进代谢紊乱和肝脏脂肪堆积的生活方式,包括不健康饮食、久坐、睡眠及昼夜节律紊乱。减重仍是非药物策略的基石,即使 modest 减重也已证明对伴或不伴肥胖的MASLD个体有益;运动与肝脂肪变、纤维化和肝细胞癌风险呈剂量依赖性降低相关。生活方式干预虽高效但实施困难,需多学科努力,长期依从性欠佳,个体反应差异大,需生物标志物研究以实现更个性化方法。
要点
- 减重是非药物策略的基石,即使 modest 减重对伴或不伴肥胖的MASLD个体均有益。
- 能量限制应结合体育活动/运动,运动效果部分独立于减重。
- 运动与肝脂肪变、纤维化和肝细胞癌风险呈剂量依赖性降低相关。
核心结论
- 生活方式干预作用于MASLD主要病理生理机制的上游,益处超越肝脏并改善心脏代谢健康。
研究设计与样本
- 综述,检索范围未在摘要中报告。
主要发现
- 不健康饮食(高能量、超加工食品、饱和脂肪、游离糖、红肉及加工肉、含糖饮料、低纤维)与久坐、睡眠及昼夜节律紊乱被确定为有害生活方式因素。
- 减重仍是非药物策略的基石,即使 modest 减重对伴或不伴肥胖的MASLD个体均有益。
- 运动与肝脂肪变、纤维化和肝细胞癌风险呈剂量依赖性降低相关。
- 生活方式改变对改善MASLD高度有效,但实施具有挑战性且需多学科努力。
- 长期依从性欠佳,个体反应差异大,需生物标志物研究以实现更个性化方法。
临床怎么用
- 以减重为核心,采用能量限制联合体育活动/运动。
- 针对不健康饮食、久坐、睡眠及昼夜节律紊乱进行生活方式干预。
- 实施需多学科团队协作,关注长期依从性。
局限性
- 综述,摘要未报告系统检索策略及纳入研究细节。
- 长期依从性欠佳,个体反应差异大,缺乏个性化生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Non-pharmacological treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) aims at modifying lifestyle patterns that promote metabolic dysfunction and hepatic fat accumulation. These include unhealthy dietary habits, which are characterised by excess energy intake and a qualitatively poor diet that is high in ultra-processed food, saturated fat, free sugar, red and processed meat and/or sweetened beverages, and low in fibre. In addition, sedentary habits, and sleep and circadian rhythm disruption have been identified as detrimental lifestyle factors. Lifestyle interventions act upstream of the main pathophysiological mechanisms driving MASLD and, therefore, provide benefits that extend beyond the liver, also improving cardiometabolic health. Weight loss remains the cornerstone of non-pharmacological strategies, and even modest weight loss has been proven beneficial in individuals with MASLD with or without obesity. To achieve weight loss, energy restriction should be combined with physical activity/exercise, since the effects of the latter are partly independent of weight reduction. Importantly, exercise is associated with a dose-dependent reduction in the risk of hepatic steatosis, fibrosis and hepatocellular carcinoma. Despite lifestyle changes proving highly effective for improving MASLD, their implementation is challenging and requires multidisciplinary efforts. Adherence is suboptimal, particularly in the long term, and the variability in individual response calls for research on biomarkers to achieve a more personalised approach. This review provides an overview of evidence of the impact of lifestyle changes/non-pharmacological interventions on MASLD.
引用
- Dufour JF, Berzigotti A. Non-pharmacological treatment of MASLD. Diabetologia. 2026. PMID: 42502137. doi:10.1007/s00125-026-06811-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。